- Home
- USAU vs CDXS Comparison
USAU vs CDXS Comparison
Compare USAU & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USAU | CDXS |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Major Chemicals |
| Sector | Basic Materials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 266.0M | 256.3M |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | USAU | CDXS |
|---|---|---|
| Price | $15.01 | $2.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $22.83 | N/A |
| AVG Volume (30 Days) | 261.4K | ★ 834.1K |
| Earning Date | 03-16-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | N/A | ★ N/A |
| Revenue | $17,402,000.00 | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $10.09 | $0.96 |
| 52 Week High | $23.72 | $3.87 |
Technical Indicators
Market Signals| Indicator | USAU | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 45.55 |
| Support Level | $14.08 | $2.29 |
| Resistance Level | $16.39 | $2.73 |
| Average True Range (ATR) | 0.69 | 0.17 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 31.83 | 38.46 |
Price Performance
Historical ComparisonAbout USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
About CDXS Codexis Inc.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.